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Experience of Cancer Care for Metastasis-Induced Acute
Pancreatitis Patients with Lung Cancer
Shih-Feng Liu, MD, Shu Zhang, MD, PhD, Yung-Che Chen, MD, Wen-Feng Fang, MD,
Meng-Chih Lin, MD, Mao-Chang Su, MD, and Chin-Chou Wang, MD
Introduction: Little information is available concerning the prog-
nosis and treatment of metastasis-induced acute pancreatitis (MIAP)
with lung cancer. The aim of this study was to investigate the
prognostic factors of MIAP patients with lung cancer.
Methods: A retrospective study of 20 MIAP patients with lung
cancer was performed. Survival was estimated using Kaplan-Meier
method. Prognostic factors were assessed with Cox proportional
hazards regression model.
Results: There were 14 men and six women; 15 cases were non-
small cell lung cancer and five cases were small cell lung cancer.
The median age was 68 (range, 41–83). The mean duration from
lung cancer to MIAP diagnosis of having MIAP was 139.8 days
(range, 3–892). However, two small cell lung cancer cases had
preceded presentation with acute pancreatitis. Chemotherapy (p 
0.008; hazards ratio 4.99; 95% confidence interval 1.51–16.54)
and an Eastern Cooperative Oncology Group (ECOG) performance
status (PS) (p  0.007; hazards ratio  6.13; 95% confidence
interval  0.04–0.61) were significant prognostic factors for sur-
vival. ECOG PS 3 to 4 at diagnosis of MIAP was 11/20. Survival of
MIAP with lung cancer was 108.7 days. Patients with ECOG PS 3
to 4 had shorter mean survival than those with PS 0 to 2 (33.7 versus
226.4 days; p  0.003). Chemotherapy group had longer mean
survival than those without chemotherapy (161.9 versus 25.0 days;
p  0.01).
Conclusion: Chemotherapy can improve survival of MIAP from
bronchogenic carcinoma in the selected patients.
Key Words: Metastasis-induced acute pancreatitis, Lung cancer,
ECOG performance, Survival.
(J Thorac Oncol. 2009;4: 1231–1235)
Pancreatic metastases are a common autopsy finding inadvanced lung cancer, but metastasis-induced acute pan-
creatitis (MIAP) is unusual.1,2 MIAP with lung cancer was
first described in a patient with small cell lung cancer (SCLC)
in 1976.1,2 The incidence of MIAP is about 3.3 to 7.5% in
lung cancer, most of which were SCLC.2,4,5 To the best of our
knowledge, most cases with MIAP with lung cancer have
been published using case reports pattern in English litera-
ture,1–11 and available data concerning the prognosis and
treatment of MIAP with lung cancer are limited.12 To better
understand these problems, we undertook a review of our
institute’s experience and a collective review of cases re-
ported in the literature.
METHODS
Study Design
This was a retrospective study on the survival rate of
MIAP patients with lung cancer. The characteristics of MIAP
patients with lung cancer and the factors affecting the cumu-
lative survival of MIAP with lung cancer were analyzed. This
study was approved by the ethics committees of our hospital
and was permitted to get an access for information reference.
Patients
Electronic search and chart reviews were performed
from January 1998 to December 2006 and MIAP patients
with lung cancer were enrolled. Tissue diagnosis of pancre-
atic metastasis was performed by fine-needle aspiration. The
diagnosis of acute pancreatitis was based on clinical, labora-
tory, and radiologic findings. The causes of acute pancreatitis,
such as alcoholism, gallbladder or biliary tract stones, abdom-
inal trauma, hyperlipidemia, hyperparathyroidism, mump infec-
tion, and drugs, were excluded. The performance status (PS) at
the diagnosis of MIAP was evaluated by Eastern Cooperative
Oncology Group (ECOG) performance scale.
Statistical Analysis
Data were shown as the case numbers and frequencies
(%) and as mean and standard error of mean. All data were
analyzed by SPSS 11.5. Survival of MIAP between SCLC
and non-small cell lung cancer (NSCLC), between with and
without chemotherapy, and between PS 3 to 4 and PS 0 to 2
were assessed using Mann-Whitney U test. The relationship
between chemotherapy and ECOG PS was described using
crosstabs. The Cox proportional hazards regression model
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was used to identify the most significant prognostic factors
for survival and to calculate the hazards ratios (HRs) of death and
95% confidence intervals (CI) for the ratio. Survival was estimated
with Kaplan-Meier method, using log-rank test. The prognostic
factors include age (65 years,  versus ); gender (male versus
female); pathologic types (SCLC versus NSCLC); ECOG PS
(PS 0–2 versus PS 3–4); chemotherapy after MIAP (yes
versus no); white cell count (10  103/L,  versus );
platelet (20  104/L,  versus ); hematocrit (10 g/dL, 
versus ); glucose (200 mg/dL,  versus ); amylase (400
U/L,  versus ); lipase (900 U/L,  versus ); albumin (3
mg/dL,  versus ); calcium (9 mg/dL,  versus ); gluta-
mate-oxalacetic transaminase (40 U/L,  versus ); glutamate
pyruvate transaminase (40 U/L,  versus ); blood urine
nitrogen (10 mg/dL,  versus ); and creatinine (1 mg/dL, 
versus ). A p value less than 0.05 was considered to be
significant.
RESULTS
Twenty cases of MIAP with lung cancer were enrolled.
The characteristics of study subjects were shown in Table 1.
TABLE 1. Characteristics of Patients with Acute Pancreatitis
Induced by Lung Cancer
Variables No. Patients(%)/Mean  SEM
Age 63.7  2.9
Male (%) 14 (70)
Pathologic type
NSCLC (%) 15 (75)
Stage IV 10
Ib 1
SCLC (%) 5 (25)
Extensive stage 5 (100)
Limited stage 0 (0)
Other metastatic sites at the
diagnosis of MIAP
Bone (%) 9 (45)
Liver (%) 8 (40)
Brain (%) 15 (25)
No liver, bone, and brain
metastasis (%)
5 (25)
Biochemical data at initial
diagnosis of MIAP
Amylase (U/L) 462.6  90.4
Lipase (U/L) 2592.3  775.9
GOT (U/L) 188.6  153.7
GPT (U/L) 250.1  215.4
Calcium (mg/dL) 9.7  0.7
Albumin (mg/dL) 3.0  0.3
Glucose (mg/dL) 117.7  12.0
Blood urine nitrogen (mg/dL) 21.1  4.9
Creatinine (mg/dL) 1.6  0.4
Hemogram at diagnosis of MIAP
White cell counts (103/L) 10.1  2.0
Platelete (104/L) 30.0  3.3
Hematocrit (%) 35.5  1.0
Hemoglobin (g/dL) 11.9  0.3
ECOG performance scale
0 (%) 0 (0)
1 (%) 5 (25)
2 (%) 4 (20)
3 (%) 5 (25)
4 (%) 6 (30)
Chemotherapy after MIAP
diagnosis (%)
8 (40)
Duration from diagnosis of lung
cancer to MIAP (d)
125.9  46.2
Duration from MIAP to death (d) 108.7  39.4
MIAP, metastasis-induced acute pancreatitis; SCLC, small cell lung cancer;
NSCLC, non-small cell lung cancer; GOT, glutamate-oxalacetic transaminase; GPT,
glutamate pyruvate transaminase.
TABLE 2. Prognostic Factors of MIAP with Lung Cancer by
Cox Proportional Hazards Regression Model
Variables No. Patients p 95% CI
Hazard
Ratio
Age 65 yr,  vs.  12 vs. 8 NS
Gender, male vs. female 14 vs. 6 NS
Pathologic type SCLC vs.
NSCLC
5 vs. 15 NS
Metastatic sites at diagnosis
of MIAP
Liver, bone, or brain
metastasis vs.
nonmetastasis
14 vs. 6 NS
Biochemical data at
diagnosis of MIAP
Amylase (U/L) 400 U/L,
 vs. 
6 vs. 14 NS
Lipase (U/L) 900 U/L,
 vs. 
13 vs. 7 NS
GOT (U/L) 40 U/L,  vs.  10 vs. 10 NS
GPT (U/L) 40 U/L,  vs.  8 vs. 12 NS
Calcium (mg/dL) 9 mg/dL,
 vs. 
13 vs. 7 NS
Albumin (mg/dL) 3 mg/dL,
 vs. 
10 vs. 10 NS
Glucose (mg/dL) 200 mg/dL,
 vs. 
4 vs. 16 NS
Blood urine nitrogen 10 mg/dL,
 vs. 
14 vs. 6 NS
Creatinine (mg/dL) 1.2 mg/dL,
 vs. 
6 vs. 14 NS
Hemogram at diagnosis
of MIAP
White cell counts, 10  103/
L,  vs. 
6 vs. 14 NS
Platelete 20  104/L,
 vs. 
15 vs. 5 NS
Hemoglobin 10 g/dL,
 vs. 
18 vs. 2 NS
Chemotherapy after MIAP,
yes vs. no
9 vs. 11 0.008 1.51–16.54 4.99
ECOG performance scale
grade 0–2 vs. 3–4
9 vs. 11 0.007 0.04–0.61 6.13
SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer; MIAP, metas-
tasis-induced acute pancreatitis; NS, not significant.
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There were 14 men and six women; 15 cases were NSCLC
and five cases were SCLC. The median age was 68 years
(range, 41–83 years), and the mean age of these patients was
63.7  2.9 years. The mean duration from lung cancer to
MIAP diagnosis of having MIAP was 139.8 days (range,
3–892). However, two cases on initial presentation had acute
pancreatitis, and SCLC was diagnosed later. Twenty-five
percent patients had no liver, bone, or brain metastasis at the
diagnosis of MIAP. Sixty percent patients failed to receive
chemotherapy at the diagnosis of MIAP. Survival of MIAP
was not associated with age, gender, biochemical and hemo-
gram data at diagnosis of MIAP, metastasis of other sites,
duration from lung cancer to diagnosis of MIAP, pathologic
type, and chemotherapy (Table 2). Chemotherapy (p 
0.008; HR  4.99; 95% CI  1.51–16.54) and an ECOG PS
(p  0.007; HR  6.13; 95% CI  0.04–0.61) were
significant prognostic factors for survival (Table 2). Kaplan-
Meier’s plot showed separate survival rate by ECOG PS
(Figure 1) and chemotherapy (Figure 2) in MIAP patients
with lung cancer.
Of the 20 MIAP patients with lung cancer, 18 patients
died, one was lost to follow-up, and one was still alive at the
date of completing this investigation. The mean survival of
MIAP with lung cancer from the date of diagnosis to death
was 108.7 days (range, 1–695 days). There were no signifi-
cant differences in survival between MIAP patients with
NSCLC or SCLC (96.1 versus 141.4 days; p 0.06). Patients
with ECOG PS 3 to 4 had shorter mean survival than those
with PS 0 to 2 (33.7 versus 226.4 days; p  0.003). Chemo-
therapy group had longer mean survival than those without
chemotherapy (161.9 versus 25.0 days; p  0.01) (Table 3).
However, seven of nine patients without chemotherapy had
PS 3 to 4, and seven of 11 patients with chemotherapy had PS
0 to 2 (Table 4). Patients with SCLC at MIAP diagnosis had
FIGURE 1. Separate survival rate of metastatic-induced
acute pancreatitis with lung cancer by Eastern Cooperative
Oncology Group (ECOG) performance status.
FIGURE 2. Separate survival rate of metastatic-induced
acute pancreatitis with lung cancer by chemotherapy.
TABLE 3. Survival of 18 MIAP Patients from Lung Cancer
with Mortalitya
Variables Mean Duration (d)a p
ECOG performance status
3–4 vs. 0–2 (n  11 vs. 7) 33.7 vs. 226.4 0.003
Pathologic type
NSCLC vs. SCLC (n  13 vs. 5) 96.1 vs. 141.4 0.06
Chemotherapy
With vs. without (n  11 vs. 7) 161.9 vs. 25.0 0.01
Chemotherapy and cell type
NSCLC
With vs. without (n  7 vs. 6) 165.0 vs. 15.6 0.04
SCLC
With vs. without (n  4 vs.1) 156.5 vs. 81.0 0.8
a Of the 20 MIAP patients with lung cancer, 18 patients died, one was lost to
follow-up, and one was still alive at the date of completing this investigation.
SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer; MIAP, metastasis-
induced acute pancreatitis.
TABLE 4. The Relationship Between ECOG Performance
Status and Chemotherapy and Between ECOG Performance
Status and Pathologic Type
ECOG Performance Status
TotalPS 0–2 PS 3–4
Chemotherapy
Yes 7 4 11
No 2 7 9
Total 9 11 20
Cell type
SCLC 4 1 5
NSCLC 5 10 15
Total 9 11 20
ECOG, Eastern Cooperative Oncology Group; SCLC, small cell lung cancer;
NSCLC, non-small cell lung cancer; MIAP, metastasis-induced acute pancreatitis.
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better ECOG PS than patients with NSCLC (80 versus 33.3%;
Table 4). The characteristic, treatment, and survival of all 20
MIAP patients with lung cancer are listed in Table 5.
DISCUSSION
Risk factor stratification was difficult in patients with
MIAP with lung cancer because of its rarity. Our series study
suggested that ECOG PS at the diagnosis of MIAP was the
determined factor for cumulative survival in these patients.
Age, gender, biochemical and hemogram data at the diagno-
sis of MIAP, metastasis of other sites, duration from lung
cancer to diagnosis of MIAP, pathologic type, and chemo-
therapy were not associated with the cumulative survival rate
of MIAP. Because pancreatic metastasis was not screened
routinely in patients with lung cancer in most clinical practice
and the incidence of MIAP was very rare, little information is
available concerning the prognosis and treatment of MIAP
patients with lung cancer. A prospective study about this
issue was not found from medical reference searching, and
we also had difficulty in collecting cases. Most articles about
this issue were retrospective, and an individual’s experience,
such as case reports, and study size are small in number.
Therefore, there were some conflicts found in different stud-
ies. For example, Ranson’s criteria were reported to predict
the clinical outcomes of patients with MIAP by Chowhan et
al,5 which was not in accordance with other studies.12 In
addition, the duration of high amylase level and chemother-
apy after MIAP were reported as the major determinants for
survival in MIAP patients with lung cancer,12 which was
against the findings of a previous study.3 The series collected
MIAP cases with lung cancer for a longer period in our
institute. Although there were only 20 patients, we thought
that the results may be convincing.
There were no significant differences in survival be-
tween MIAP patients with NSCLC and SCLC. However,
SCLC had longer average survival than NSCLC (141.4 ver-
sus 96.1 days). Our explanation is that SCLC tends to earlier
pancreatic metastasis and has better PS at MIAP diagnosis
than NSCLC. Most MIAP patients with NSCLC died within
2 weeks (range, 2 days to 8 weeks) under supportive therapy,3
only cases reported were suggested to receive polychemo-
therapy.2,4 Our study also showed that chemotherapy could
improve survival of MIAP from bronchogenic carcinoma in
the selected patients. At the diagnosis of MIAP with NSCLC,
most patients at advanced stage with poor PS subsequently
refused to or could not receive chemotherapy. In our study,
MIAP with NSCLC patients with chemotherapy had longer
survival than those without chemotherapy. In addition,
NSCLC patients with chemotherapy having better PS were
also an important factor for their longer survival.
Most SCLC patients with MIAP died within 3 weeks
(range, 1–8 weeks), if they did not receive specific treat-
ment.4,5,9 For SCLC patients with MIAP, aggressive chemo-
therapy has been recommended.4 Four patients at advanced
stage responded to chemotherapy, with a survival of 4 to 6
months. In contrast, the other two patients unresponsive to
chemotherapy died within 2 weeks.4 Although our results
cannot get to the statistical significance, in our study, SCLC
TABLE 5. The Characteristics Treatment and Survival of All 20 MIAP Patients with Lung Cancer
Patient No Gender Age Pathology PS Chemotherapy Survival (d)
1 M 44 SCLC 1 VP 16  CDDP  6 cycles 229
2 F 44 SCLC 1 VP 16  CDDP  4 cycles 97
3 M 51 SCLC 2 VP 16  CDDP  4 cycles 266
4 M 75 SCLC 2 VP 16  CDDP  3 cycles 34
5 F 68 SCLC 4 Nil 81
6 M 79 SCC 4 Gemcitabine  CDDP  one dose 14
7 M 70 Adenocarcinoma 1 Gemcitabine  CDDP  6 cycles 210
Docetaxel  3 cycles
8 M 70 SCC 2 MVP  2 cycles; gemcitabine  5 cycles
Docetaxel  4 cycles
695
9 M 41 NSCLC 1 Nil Lost to follow-up
10 F 68 SCC 4 Nil 12
11 M 61 Adenocarcinoma 3 Nil 1
12 F 52 NSCLC 3 Nil 14
13 M 67 Adenocarcinoma 3 Nil 16
14 F 73 SCC 4 Nil 29
15 M 83 SCC 3 Nil 22
16 M 75 NSCLC 3 Gemcitabine monotherapy  3 cycles 109
17 M 78 Adenocarcinoma 4 Gefitinib 58
18 M 61 NSCLC 4 Gemcitabine  CDDP  one dose 15
19 M 45 Adenocarcinoma 2 Docetaxel  CDDP  2 cycles 54
20 F 68 Adenocarcinoma 1 Nil Alive
SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma; MIAP, metastasis-induced acute pancreatitis.
M: mitomycin; V: VP16; P: cisplatin.
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patients with chemotherapy also had longer survival than
those without chemotherapy. The range of survival (of 34–
266 days) in SCLC patients with chemotherapy may be due
to variable response to chemotherapy (Table 5). Conversely,
the mean survival of our series was longer than that of
previously reported cases either in SCLC or in NSCLC
patients. We thought that our cases had better PS at MIAP
diagnosis and better response to chemotherapy.
This study has some limitations. First, this study is a
retrospective study and the number of patients is too small.
Our patients with lung cancer were not examined routinely to
screen whether patients with lung cancer had pancreatic
metastasis. The patients with MIAP were diagnosed mainly
owing to their clinical manifestations and subsequent blood
biochemical study and imaging studies. In fact, some lung
cancer patients with MIAP, especially patients with SCLC,
have no obvious symptoms and were easily underdiagnosed.
Thus, the real incidence of MIAP in lung cancer is much
more than our collection. Second, some chemotherapy regi-
mens were used according to former guidelines. However, the
advance of new chemotherapy for lung cancer is noted in
recent years, and the update regimen may have better results
for these patients.
In conclusion, chemotherapy can improve survival of
MIAP from bronchogenic carcinoma in the selected patients.
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